| Survival: | 6.6 months |
| Toxicity Grade: | 4 |
| Treatments: | Chemotherapy |
| Drugs: | Leucovorin |
| Country: | United States |
| City/State/Province: | Chicago, Illinois |
| Hospital: | University of Chicago Medical Center |
| Journal: | Link |
| Date: | 11/1999 |
| Description |
| Patients: This Phase II study involved 20 patients with malignant mesothelioma who could not be treated by surgery or radiation alone. Treatment: The treatment consisted of administration of the drug edatrexate with leucovorin. Toxicity: Grade 3-4 toxicities included hematologic, infection, muscositis, esophagitis/dysphagia, dermatologic, anorexia, malaise/fatigue, cardiac, pulmonary, hepatic, and neurologic. Results: The median survival duration was 6.6 months. |